Supplement Bioavailability: What It Is and How to Maximize It

You take a supplement every morning. But how much of that compound actually reaches where it needs to go? Bioavailability is the factor that determines the difference between a supplement that works and one that simply passes through your body without leaving a trace. And yet it is the concept most often overlooked on labels, in price comparisons, and in purchasing decisions.

The bioavailability of supplements is not a pharmacological technicality reserved for researchers. It is one of the most practical criteria available for judging whether a supplement is worth what it costs. A product with 20% oral bioavailability may require five times the dose of one with 90% to produce the same physiological effect. That has direct implications for efficacy, safety, and the real cost per active dose.

This guide explains what bioavailability is, the factors that determine it, how it varies by nutrient type, and which strategies—backed by clinical evidence—help you maximize it. By the end, you will have the criteria to evaluate any supplement with scientific rigor.

Important notice: This article is for informational and educational purposes. It does not constitute medical advice and is not a substitute for consulting a qualified healthcare professional. Talk to your doctor or pharmacist before starting any supplementation regimen, especially if you take medication or have diagnosed health conditions.

What Bioavailability Is: Definition and Why It Is Not the Same as the Dose

Bioavailability is defined as the fraction of an administered substance that reaches the systemic circulation in active form and is available to exert its physiological effect (Shargel & Yu, 2016). In practical terms: if you take 500 mg of a compound and only 100 mg reaches your bloodstream in a usable form, the oral bioavailability of that compound is 20%.

This definition, established in clinical pharmacology, applies directly to food supplements. The European Food Safety Authority (EFSA) recognizes bioavailability as a decisive parameter for assessing the efficacy of nutrients and the adequacy of reference doses (EFSA Panel on Dietetic Products, Nutrition and Allergies, 2013).

Absolute vs. relative bioavailability

There are two ways to measure bioavailability:

• Absolute bioavailability: compares oral absorption with intravenous administration (the 100% reference). It is the classic pharmacological standard.
• Relative bioavailability: compares two oral formulations against each other. It is the most relevant metric for comparing supplements on the market.

When a manufacturer claims its formulation has “higher bioavailability,” it should always specify: higher than what? Measured how? In which population? Without those details, the claim has no scientific value.

Why the label dose is not the active dose

The dose listed on a supplement label is the administered dose, not the absorbed dose. The difference can be substantial. A review published in Current Nutrition and Food Science analyzed the bioavailability of different forms of magnesium and concluded that they show bioavailability differences—generally modest and dependent on the dose and the individual's magnesium status, rather than on the type of salt (Schuchardt & Hahn, 2017). Even so, the chemical form matters: 400 mg of magnesium oxide do not necessarily equal 400 mg of magnesium glycinate in terms of absorbed magnesium.

This distinction has direct consequences:

1. Efficacy: an insufficient dose of the active compound does not produce the expected effect, even if the label states a seemingly high amount.
2. Safety: very high bioavailability can increase the risk of adverse effects if the dose is not adjusted.
3. Real cost: the price per labeled milligram is irrelevant; the price per absorbed milligram is the correct economic indicator.

The Five Barriers That Reduce Supplement Bioavailability

For a nutrient to reach the target cell, it must overcome a series of physiological barriers. Understanding these barriers is essential to grasp why the same molecule can have radically different bioavailability depending on its chemical form, the timing of administration, or the presence of other compounds.

Barrier 1: Dissolution and release in the gastrointestinal tract

Before being absorbed, the compound must dissolve in the aqueous environment of the gastrointestinal tract. Solid forms (capsules, tablets) have to disintegrate first. The speed and completeness of this process depend on the galenic formulation, gastric pH, and the presence of food.

Enteric-coated tablets are designed not to dissolve in the stomach (pH 1.5–3.5) and to release their contents in the small intestine (pH 6–7.4), where absorption is more efficient for certain compounds. This strategy improves the bioavailability of nutrients sensitive to gastric acid, such as some forms of vitamin B12.

Barrier 2: Intestinal absorption

The small intestine is the main site of absorption. Enterocytes (the cells of the intestinal epithelium) absorb nutrients through different mechanisms:

• Active transport: requires specific carrier proteins and energy. It has limited capacity and can become saturated (iron, calcium, zinc).
• Passive diffusion: requires no energy but depends on the concentration gradient. It favors small lipophilic molecules.
• Endocytosis: for large molecules or complexes.

Saturation of active transporters is a common cause of reduced bioavailability at high doses. In the case of calcium, the absorbed fraction tends to decrease as the dose in a single intake increases, due to saturation of active transport. At low doses, active transport—efficient but saturable—predominates; at high doses, absorption relies mainly on passive diffusion, a less efficient mechanism. The result: more does not always mean more absorbed.

Barrier 3: Hepatic first-pass effect

After intestinal absorption, nutrients pass through the portal vein to the liver before reaching the systemic circulation. The liver can metabolize a significant fraction of the absorbed compound, reducing the amount that reaches the rest of the body. This “first-pass effect” is especially relevant for lipophilic compounds and certain polyphenols.

Curcumin illustrates the problem well: it has extremely low oral bioavailability (< 1% in its free form), partly because of intensive hepatic metabolism and partly because of poor intestinal absorption. Hence the interest in formulations that bypass this barrier, such as lipid nanoparticles or phospholipid complexes.

Barrier 4: Nutrient interactions

The presence of other compounds in the gastrointestinal tract can increase or reduce the absorption of a nutrient. Some interactions are well known:

• Inhibitory interactions: calcium inhibits the absorption of both heme and non-heme iron. Although the exact mechanism is not fully elucidated, the inhibitory effect is well documented in human clinical studies. The phytates present in whole grains and legumes markedly reduce zinc absorption (Lönnerdal, 2000). The oxalate in spinach forms insoluble complexes with calcium.
• Enhancing interactions: vitamin C increases the absorption of non-heme iron by reducing Fe³⁺ to Fe²⁺, a more soluble form (Lynch & Cook, 1980). Vitamin D is essential for the active absorption of calcium.

This is why the timing and combination of supplements are not irrelevant from the standpoint of efficacy.

Barrier 5: Distribution and tissue uptake

Even after reaching the systemic circulation, the compound must reach the target tissue and be taken up by the cells. Factors such as binding to plasma proteins, lipid solubility, and the expression of specific transporters in the tissues determine the final distribution.

NAD+ (nicotinamide adenine dinucleotide) is an example that deserves special attention in the context of cellular vitality: it cannot cross the cell membrane directly. Cells must synthesize it internally from precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), which are taken up by specific transporters. That is why the bioavailability of NAD+ precursors is measured not only in plasma, but by the intracellular rise in NAD+.

Bioavailability by Nutrient Type: Vitamins, Minerals, and Bioactive Compounds

There is no “average” bioavailability for supplements. Each class of nutrient has its own absorption characteristics, and within each class, the chemical form makes substantial differences.

Fat-soluble vitamins (A, D, E, K)

Fat-soluble vitamins require the presence of dietary fat to be absorbed efficiently. They are incorporated into the micelles formed during lipid digestion and absorbed together with fatty acids. Their bioavailability increases significantly when taken with a meal that contains fat.

The numbers are telling: a randomized clinical trial in 50 older adults documented that a single dose of vitamin D3 taken with a meal containing fat was absorbed up to 32% better than when taken with a fat-free meal (Dawson-Hughes et al., 2015). A difference with practical implications for people with vitamin D insufficiency.

Among the fat-soluble vitamins, the chemical form also matters: vitamin K2 in the form of MK-7 (menaquinone-7) has a much longer plasma half-life than vitamin K1 (phylloquinone), which translates into more stable plasma levels at the same dose (Schurgers et al., 2007).

Water-soluble vitamins (B complex, vitamin C)

Water-soluble vitamins do not require fat to be absorbed, but they are subject to transporter saturation at high doses. Vitamin C has a bioavailability close to 90% at doses of 100–200 mg, but it drops to 50% at 1,000 mg and to 16% at 12,000 mg. The excess is eliminated in urine, which explains why megadoses of vitamin C do not produce proportionally higher plasma levels.

Vitamin B12 deserves a special mention: its absorption depends on gastric intrinsic factor, a glycoprotein produced by the parietal cells of the stomach. At oral doses of 1–2 µg, absorption is 40–60%. At doses of 500–1,000 µg (as in many supplements), passive-diffusion absorption—without intrinsic factor—can compensate for an intrinsic factor deficiency, which is relevant in older adults and vegans.

Minerals: the chemical form changes everything

The bioavailability of minerals varies enormously depending on their chemical form. The following table summarizes the available evidence:

Sources: Schuchardt & Hahn (2017); Lönnerdal (2000); Olivares et al. (2012)

Chelated forms (bound to amino acids such as glycine) tend to have higher bioavailability because they use the intestinal dipeptide transporters (PepT1), which have greater capacity than mineral-specific transporters. In the specific case of magnesium, the differences between its organic forms are detailed in our comparison of magnesium bisglycinate and citrate.

Bioactive compounds: the challenge of low natural bioavailability

Many bioactive compounds of interest for cellular vitality have intrinsically low oral bioavailability. This has driven the development of formulation technologies to improve it:

• Curcumin: bioavailability < 1% in free form. Formulations with piperine (an inhibitor of hepatic and intestinal metabolism) increased plasma bioavailability by up to 2,000% in a study with 10 volunteers (Shoba et al., 1998), although it should be borne in mind that piperine can interact with medications metabolized through the same enzymatic pathways. Lipid formulations (Meriva®, Theracurmin®) show 20–45-fold increases in comparative studies.
• Resveratrol: although intestinal absorption is high (~70%), extensive metabolism in both the intestine and the liver (through sulfation and glucuronidation) reduces the systemic bioavailability of free resveratrol to less than 1%. The conjugated metabolites circulate in plasma, but their biological activity is lower than that of the parent compound. The trans-resveratrol form is more stable than the cis form.
• Coenzyme Q10: the ubiquinol (reduced) form shows higher bioavailability than ubiquinone (oxidized), with plasma levels roughly 1.7 times higher for ubiquinol than for ubiquinone (Langsjoen & Langsjoen, 2014).
• NAD+ precursors (NR, NMN): nicotinamide riboside (NR) is orally bioavailable and raises blood NAD+ levels in both mice and humans (Trammell et al., 2016), and it has been the subject of clinical trials that measured its effect on blood NAD+ levels. Martens et al. (2018) documented increases in blood NAD+ in participants who received NR at a dose of 1,000 mg/day for 6 weeks. NMN has also shown effects on plasma NAD+ in preliminary studies, although direct comparative trials in humans are more limited.

Individual Factors That Modify Bioavailability

Bioavailability is not a biological constant. It varies between individuals and within the same individual depending on multiple physiological and lifestyle factors. Ignoring this variability is one of the most common errors in interpreting studies on supplements.

Age

Aging reduces the bioavailability of several nutrients through different mechanisms:

• Hypochlorhydria: gastric acid production declines with age in a significant proportion of people over 60. This reduces the absorption of nutrients that require an acidic pH to dissolve, such as non-heme iron, calcium carbonate, and protein-bound vitamin B12.
• Reduced intestinal absorptive surface: atrophy of the intestinal villi reduces the capacity for active absorption.
• Lower transporter expression: the expression of vitamin D and calcium transporters declines with age, contributing to the higher prevalence of calcium and vitamin D deficiency in older adults.

Cohort data illustrate the scale of the problem: a significant proportion of people over 65 show subclinical vitamin B12 deficiency (serum levels < 148 pmol/L) despite an apparently adequate dietary intake, largely attributable to malabsorption from hypochlorhydria. A correct intake does not guarantee correct absorption.

Prior nutritional status

The body actively regulates the absorption of many minerals according to its reserves. Iron absorption can increase from 5–10% in people with normal reserves to 20–30% in people with iron deficiency. Zinc follows a similar pattern. This homeostatic regulation has important implications: supplementing with iron in people with normal reserves does not raise serum levels proportionally, but it can increase the risk of gastrointestinal adverse effects.

Gut microbiome

The gut microbiota influences the bioavailability of several nutrients. Gut bacteria produce vitamin K2 (menaquinones), contribute to the conversion of vitamin B precursors, and modulate the absorption of polyphenols. Polyphenols such as flavonoids are largely metabolized by the microbiota before being absorbed; the resulting metabolites (urolithins, equol) may have greater or lesser biological activity than the parent compound.

This is one of the reasons why two people can respond very differently to the same polyphenol supplement. People with a greater abundance of certain gut bacteria such as Gordonibacter urolithinfaciens produce more urolithin A from ellagitannins (present in pomegranates and walnuts). Urolithin A has been shown to activate mitophagy (mitochondrial renewal) in preclinical studies and in a phase I clinical trial in humans, although research into its long-term functional benefits is ongoing.

Genetic polymorphisms

Genetic variants in genes that encode metabolic enzymes and nutrient transporters can substantially alter how nutrients are used:

• MTHFR (C677T): the most studied polymorphism in nutrition. People with the TT genotype (present in roughly 10–15% of the European population) have reduced activity of the enzyme methylenetetrahydrofolate reductase, which makes it harder to convert folic acid into its biologically active form (5-MTHF). For these individuals, methylfolate (5-MTHF) is of greater practical use than standard folic acid, since it does not require that enzymatic conversion.
• VDR (vitamin D receptor): polymorphisms in the vitamin D receptor gene modify the response to vitamin D3 supplementation.
• SLC30A8 (zinc transporter): variants in this gene are associated with differing efficiency in zinc metabolism.

Medications

Drug–nutrient interactions are a common and underestimated cause of reduced bioavailability:

• Proton pump inhibitors (omeprazole, pantoprazole) reduce gastric acid and decrease the absorption of vitamin B12, iron, calcium, and magnesium.
• Metformin (an antidiabetic) is associated with a reduction in serum vitamin B12 levels of approximately 20–30%, due to inhibition of its absorption in the terminal ileum.
• Bile acid sequestrants (cholestyramine) reduce the absorption of fat-soluble vitamins.
• Calcium and iron reduce the absorption of thyroxine (levothyroxine) when taken at the same time.

This is a compelling reason to talk to a healthcare professional before starting any supplementation regimen, especially if you already take chronic medication.

Formulation Technologies That Improve Bioavailability

The pharmaceutical and food supplement industries have developed various technologies to overcome the bioavailability limitations of nutrients. Some have solid clinical evidence; others are at more preliminary stages of research.

Chelated mineral forms

Chelation involves binding a mineral to an amino acid or peptide to improve its absorption. Amino acid chelates (bisglycinate, glycinate) use the dipeptide transporter PepT1, which has greater capacity and specificity than inorganic mineral transporters. In comparative studies, ferrous bisglycinate has been associated with a hemoglobin response at least equivalent to that of ferrous sulfate at the same dose of elemental iron, and with a lower frequency of gastrointestinal adverse effects.

Liposomes and lipid nanoparticles

Liposomes are spherical vesicles formed by lipid bilayers that encapsulate the nutrient. They mimic the structure of cell membranes, which facilitates fusion with enterocytes and direct absorption. This technology is especially useful for hydrophilic compounds with low intestinal permeability and for lipophilic compounds with low aqueous solubility.

A study published in Nutrition and Metabolic Insights compared liposomal vitamin C with standard vitamin C in 11 participants and found that the liposomal form produced plasma levels 1.77 times higher at the same dose (Davis et al., 2016). Studies in this field are still limited in number and sample size; more robust clinical trials are needed to establish definitive recommendations.

Phospholipid complexes (phytosomes)

Phytosome technology binds the bioactive compound to phospholipids (mainly phosphatidylcholine), creating a complex that improves solubility in the intestinal environment and permeability across the membrane. Meriva® (curcumin–phospholipid) is the most studied example: a comparative clinical trial showed a relative bioavailability 29 times higher than standard curcumin, measured by the area under the plasma curve (Cuomo et al., 2011).

Micronization and nanonization

Reducing particle size increases the contact surface with gastrointestinal fluids, accelerating dissolution. Micronization (particles of 1–100 µm) and nanonization (< 1 µm) are strategies used for compounds with low aqueous solubility. Theracurmin® (nanonized curcumin) showed a bioavailability 27 times higher than standard powdered curcumin in a pharmacokinetic study (Sasaki et al., 2011).

First-pass metabolism inhibitors

Piperine (a black pepper extract) inhibits CYP3A4 enzymes and hepatic and intestinal glucuronidation, reducing the first-pass metabolism of several compounds. With curcumin, the addition of 20 mg of piperine increased bioavailability by 2,000% in a crossover study with 10 volunteers (Shoba et al., 1998). The inhibition of CYP3A4, however, can interfere with the metabolism of medications that use this pathway, which should be taken into account in people on multiple medications.

Modified-release forms

Sustained-release or pulsatile-release formulations help maintain more stable plasma levels throughout the day, avoiding the peaks and troughs associated with immediate release. This is especially relevant for nutrients with a narrow therapeutic window or for compounds whose absorption becomes saturated at high doses (such as vitamin C).

How to Maximize Bioavailability: Practical, Science-Based Strategies

Knowledge about bioavailability has immediate practical value. These are the most scientifically supported strategies for maximizing the absorption of the most common supplements.

1. Take your supplements at the right time

The timing of administration relative to meals is one of the most modifiable factors and one with the greatest impact on bioavailability:

• With a fatty meal: fat-soluble vitamins (A, D, E, K), coenzyme Q10, curcumin, omega-3. The presence of lipids stimulates bile secretion and micelle formation, which are essential for the absorption of lipophilic compounds.
• Fasting or on an empty stomach: iron (the absence of calcium and phytates improves absorption), some amino acids (to avoid competition with other dietary amino acids).
• Independent of meals: magnesium citrate or glycinate, vitamin C, and most B vitamins at standard doses.
• Separated from other supplements: calcium and iron should not be taken together; zinc and copper compete for the same transporters.

2. Choose the right chemical form

Based on the evidence summarized above, the forms with the highest demonstrated bioavailability are:

• Magnesium: glycinate or citrate (over oxide)
• Iron: ferrous bisglycinate (over ferrous sulfate, with fewer GI effects)
• Zinc: glycinate or citrate (over oxide)
• Vitamin B12: methylcobalamin or adenosylcobalamin (active forms, especially relevant in older adults)
• Folate: methylfolate (5-MTHF) in people with the MTHFR polymorphism
• Vitamin K: MK-7 (menaquinone-7) for longer-lasting effects
• Coenzyme Q10: ubiquinol in people over 50

3. Consider nutrient interactions

Some combinations enhance absorption; others inhibit it. The most relevant ones:

Synergistic combinations:

• Vitamin C + non-heme iron: vitamin C reduces Fe³⁺ to Fe²⁺ and forms soluble complexes that improve absorption by up to 67% (Lynch & Cook, 1980).
• Vitamin D + calcium: active vitamin D (calcitriol) is essential for the expression of the calcium transporter in the intestine.
• Vitamin K2 + vitamin D: vitamin D increases the synthesis of vitamin K–dependent proteins (osteocalcin, MGP), so taking them together may support better use of both.
• Dietary fat + fat-soluble vitamins: already mentioned.

Combinations to avoid or separate:

• Calcium + iron: documented inhibitory effect. Separate by at least 2 hours.
• Zinc + copper: high doses of zinc reduce copper absorption. If supplementing with zinc long-term, consider adding copper.
• Calcium + zinc: at high doses, calcium can reduce zinc absorption.

4. Optimize gastrointestinal health

A healthy gastrointestinal tract is the best enhancer of bioavailability. Factors that improve nutrient absorption:

• Maintain a diverse microbiota (a diet rich in fermentable fiber and fermented foods).
• Avoid the unnecessary use of proton pump inhibitors, which reduce the absorption of multiple nutrients.
• Look after the integrity of the intestinal mucosa through a varied diet, since an impaired intestinal barrier can affect nutrient absorption.

5. Respect the doses used in clinical studies

More is not always better. For nutrients with saturable absorption, doses split throughout the day can be more effective than a single high dose. Vitamin C, calcium, and iron are the clearest examples. It has been reported that 500 mg of calcium in two daily intakes produces a higher total absorption than 1,000 mg in a single intake (Heaney et al., 2000).

For NAD+ precursors such as nicotinamide riboside (NR), the published clinical trials have used doses of 1,000–2,000 mg/day and have measured blood NAD+ levels as a pharmacokinetic marker: Martens et al. (2018) used 1,000 mg/day for 6 weeks, and Dollerup et al. (2018), 2,000 mg/day for 12 weeks. Both trials documented that these doses were well tolerated.

How to Read a Supplement Label with Scientific Judgment

The label of a food supplement contains information regulated by Regulation (EU) 1169/2011 on food information and by specific food supplement legislation. Knowing how to interpret it lets you make purchasing decisions based on data, not on marketing.

Declared dose vs. active dose

The label must indicate the amount of nutrient per serving. But as we have seen, this amount is the administered dose, not the absorbed dose. To assess the real active dose, you need to know the bioavailability of the specific chemical form used.

Some manufacturers declare the chemical form of the ingredient (e.g., “magnesium as magnesium bisglycinate”), which makes it possible to estimate bioavailability. Others declare only the elemental mineral without specifying the form, which makes evaluation harder.

Equivalences and active forms

Some nutrients are expressed in equivalents of the active form:

• Beta-carotene is expressed in retinol equivalents (RAE): 12 µg of beta-carotene = 1 µg RAE.
• Folate can be expressed in µg of folic acid or in µg of dietary folate equivalents (DFE): 1 µg of folic acid = 1.7 µg DFE.
• Vitamin E is expressed in mg of alpha-tocopherol equivalents.

Nutrient Reference Values (NRV)

The NRV (Nutrient Reference Value) percentages on the label are based on the reference intakes established by EFSA for the general population. These values do not take into account the variable bioavailability between chemical forms or individual needs. A supplement that provides 100% of the NRV for magnesium in oxide form may effectively provide less absorbable magnesium than one that provides 50% of the NRV in glycinate form.

Excipients and their impact on bioavailability

Excipients (non-active ingredients) can influence bioavailability:

• Positively: phospholipids (sunflower lecithin) improve the absorption of lipophilic compounds; piperine improves the absorption of curcumin.
• Negatively: some binders and fillers can slow the rate of dissolution; excess magnesium stearate can form a hydrophobic layer that slows the release of the active ingredient.

Quality signals on the label

Some indicators that a manufacturer prioritizes bioavailability and quality:

• Specification of the chemical form of the active ingredient (not just the generic mineral or vitamin).
• Reference to clinical studies or to patented ingredients with published evidence.
• Third-party certifications (NSF, USP, Informed Sport) that verify the declared composition.
• The absence of claims not authorized by EFSA is, paradoxically, a sign of rigor: manufacturers that limit their claims to what the evidence supports tend to prioritize quality over marketing.

Bioavailability is the parameter that turns the declared dose into a real effect. And it is also the criterion most often overlooked at the moment of purchase. A high-quality supplement is not the one with the highest dose on the label: it is the one that ensures the largest possible fraction of that dose reaches the cells in active form.

The criteria for evaluating it are concrete: the chemical form of the ingredient, the presence of enhancers or inhibitors, formulation technology backed by studies in humans, and suitability for the individual profile—age, nutritional status, medication, genetics. With that information, the decision stops being a gamble and becomes an informed choice.

At PLENIAGE®, the design of our formulations starts from the principles described in this article: selecting chemical forms with higher bioavailability according to the available scientific literature, specifying the chemical form on the label, and avoiding claims that exceed the published evidence.

If you want to dig deeper into how these principles apply to specific ingredients such as nicotinamide riboside (NR), magnesium, or vitamin D, explore the rest of the articles on the PLENIAGE® blog, where each ingredient is analyzed with the same scientific rigor.

Notice: This article is for informational and educational purposes. It does not constitute medical advice and is not a substitute for consulting a qualified healthcare professional.